SLC5A2 and type 2 diabetes mellitus: T2DM patients frequently exhibit increased ectopic fat accumulation [29] and a progressive decline in muscle mass and quality [30], and it is by fat mass reduction that treatment with SGLT2 inhibitors reduces body weight [22].